IMO I think, even at 8c, it serves both the interest of PYC and the interest of shareholders alike because with adequate funding PYC will be in a much stronger position to negotiate a business asset deal, if they so choose to do so. AT has already stumped up another $24m in the accelerated part, and I would suggest he sees the value of this capital raising which could also suggest seemingly great confidence in PYC's probability of successful outcomes as they advance their pipeline assets through clinical trials.
In contrast, I think many retailer investors who hold PYC would be screaming from the rooftops if they didn't get an opportunity to participate in the capital raising. At the end of the day it will come down to the choice of each individual shareholder to choose what is right for them. Please don't rely on my point of view, ultimately it is up to you.
PYC Price at posting:
8.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)